Online inquiry

IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14299MR)

This product GTTS-WQ14299MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets ANGPT2&VEGFA gene. The antibody can be applied in Solid tumors, Colorectal Cancer (CRC) Cancers (CRC) Cancer (CRC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001118887.2; NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 285; 7422
UniProt ID O15123; P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ14299MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3387MR IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AT-005
GTTS-WQ1619MR IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACE-910
GTTS-WQ14692MR IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SCT-400
GTTS-WQ3955MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ8249MR IVTScrip™ mRNA-Anti-PDCD1, HLX10(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA HLX10
GTTS-WQ5464MR IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CDB-1
GTTS-WQ8125MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HH1
GTTS-WQ11854MR IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MK-7684
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW